AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10355012 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 0
Study 7503000 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrelin (dosing regimens: 180 and 135 micrograms/kg bolus, followed by 0.75 micrograms/kg/min infusion)
Number of subjects: 73
Study 7503000 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrelin (0.50 micrograms/kg/min infusion)
Number of subjects: 73
Study 7503000 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrelin with aspirin and heparin
Number of subjects: 73
Study 7503000 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrelin
Number of subjects: 73
Study 7503000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 2023749 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol treatment
Number of subjects: 143
Study 2023749 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 143
Study 7016244 — intervention group
Group type: EXPERIMENTAL
Intervention: Stripping of the long saphenous vein
Number of subjects: 2
Study 7016244 — intervention group
Group type: COMPARATOR
Intervention: No stripping of the long saphenous vein
Number of subjects: 2
Study 29125017 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 sets of resistance training (G3S, n = 20)
Number of subjects: 62
Study 29125017 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 set of resistance training (G1S, n = 21)
Number of subjects: 62
Study 29125017 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 21)
Number of subjects: 62
Study 28288570 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15, 30 and 45 mg
Number of subjects: 15
Study 28288570 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan with NO-inhibition
Number of subjects: 15
Study 28288570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 25796417 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic stents in the curative setting
Number of subjects: 96
Study 25796417 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic stents for palliation
Number of subjects: 96
Study 25796417 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for curable disease
Number of subjects: 96
Study 25796417 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic stents vs surgery
Number of subjects: 96
Study 23780373 — intervention group
Group type: EXPERIMENTAL
Intervention: Midday moderate-intensity exercise (45 minutes)
Number of subjects: 10
Study 23780373 — intervention group
Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 10
Study 21086279 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine/benzydamine plus paracetamol
Number of subjects: 164
Study 21086279 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paracetamol
Number of subjects: 164
Study 18436178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 0
Study 18436178 — intervention group
Group type: COMPARATOR
Intervention: Imipenem
Number of subjects: 0
Study 16796925 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition (Supportan and glutamine, calorific value of 125.4 kJ.kg(‐1).d(‐1), given orally or by nasointestinal tube for 5 days before operation, and through nasointestinal tube post-operatively from day 2 to day 9)
Number of subjects: 80
Study 16796925 — intervention group
Group type: COMPARATOR
Intervention: Control group (Nutrition with the same calorific value given in the same manner)
Number of subjects: 80
Study 14604457 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy in patients who developed depression within the first 4 weeks
Number of subjects: 146
Study 14604457 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy in patients who developed depression later
Number of subjects: 146
Study 14604457 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha therapy in patients with no psychiatric symptoms
Number of subjects: 146
Study 10794114 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical acupuncture
Number of subjects: 132
Study 10794114 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 132
Study 9038464 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia using morphine 1 mg bolus with a 10-min lockout and no background infusion
Number of subjects: 30
Study 9038464 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular codeine phosphate
Number of subjects: 30
Study 1886957 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak visual stimuli presented at 0, 150, 250, 350, or 500 ms after the R-wave of the electrocardiogram with an intensity yielding either 63% or 90% correct detections
Number of subjects: 24
Study 1886957 — intervention group
Group type: COMPARATOR
Intervention: Instructions to judge which of two weak visual stimuli occurred
Number of subjects: 24
Study 1886957 — intervention group
Group type: COMPARATOR
Intervention: Instructions to execute a speeded, discriminative response to the stimuli
Number of subjects: 24
Study 6138089 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 15
Study 6138089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3993546 — intervention group
Group type: COMPARATOR
Intervention: Propranolol, 160 mg/day
Number of subjects: 47
Study 3993546 — intervention group
Group type: COMPARATOR
Intervention: Atenolol, 100 mg/day
Number of subjects: 47
Study 3993546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31983653 — intervention group
Group type: EXPERIMENTAL
Intervention: CNIC polypill (atorvastatin 40mg/ramipril 10mg/aspirin 100mg)
Number of subjects: 241
Study 31983653 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (40mg)
Number of subjects: 241
Study 31983653 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (10mg)
Number of subjects: 241
Study 29478933 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.014" A‐NiTi (n=30)
Number of subjects: 59
Study 29478933 — intervention group
Group type: COMPARATOR
Intervention: 0.016" Heat Activated NiTi (HANT) (n=29)
Number of subjects: 59
Study 28033332 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Renin Inhibitor (DRI) - Aliskiren
Number of subjects: 225
Study 28033332 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin Receptor Blockers (ARBs)
Number of subjects: 225
Study 25006068 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilpaterol hydrochloride (ZH; 8.3 mg/kg [100% DM basis]) for 20 d
Number of subjects: 2275
Study 25006068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ractopamine hydrochloride (RH; 30.1 mg/kg [100% DM basis]) for 28 d
Number of subjects: 2275
Study 25006068 — intervention group
Group type: COMPARATOR
Intervention: Control diet containing no β‐agonists
Number of subjects: 2275
Study 22865016 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined behavioral management and medication management intervention
Number of subjects: 573
Study 22865016 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 573
Study 20230350 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-compensable patients
Number of subjects: 391
Study 20230350 — intervention group
Group type: COMPARATOR
Intervention: Non-compensable patients
Number of subjects: 391
Study 18373127 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention (n = 46)
Number of subjects: 88
Study 18373127 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 42)
Number of subjects: 88
Study 15855334 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 30
Study 15855334 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 30
Study 15855334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15855334 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 30
Study 12208438 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg) + Thiopental (3 mg/kg)
Number of subjects: 40
Study 12208438 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (5 mg/kg)
Number of subjects: 40
Study 10350250 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 42
Study 10350250 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 42
Study 7536833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention improving energy and nutrient intakes of women and preschool children
Number of subjects: 0
Study 7536833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 0
Study 1828191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorodeoxyuridine (FUdR) at a dose of 0.3 mg/kg per day with oral leucovorin (LV) at a dose of 100 mg every hour for four doses before FUdR infusion and then every 4 hours during FUdR treatment.
Number of subjects: 24
Study 1828191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorodeoxyuridine (FUdR) at a dose of 0.25 mg/kg per day with oral leucovorin (LV).
Number of subjects: 24
Study 1828191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorodeoxyuridine (FUdR) at a dose of 0.375 mg/kg per day with oral leucovorin (LV).
Number of subjects: 24
Study 7469003 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 450
Study 7469003 — intervention group
Group type: COMPARATOR
Intervention: Control (no promethazine)
Number of subjects: 450
Study 7469003 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosil (as a histamine blocker)
Number of subjects: 450
Study 7469003 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reactions among females
Number of subjects: 450
Study 31430369 — intervention group
Group type: EXPERIMENTAL
Intervention: BIC/FTC/TAF
Number of subjects: 570
Study 29242062 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injections of allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSCs) at a dosage of 5 × 10^6 MSCs per injection, 30 injections total.
Number of subjects: 66
Study 29242062 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections (control group).
Number of subjects: 66
Study 26746242 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for aggression (low maternal monitoring, depressed affect, anger reactivity)
Number of subjects: 399
Study 26746242 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor conflict management skills
Number of subjects: 399
Study 26746242 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance of dating violence
Number of subjects: 399
Study 26746242 — intervention group
Group type: EXPERIMENTAL
Intervention: None of the examined risk factors were unique to aggression type
Number of subjects: 399
Study 24505303 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving an apology from player A to player B
Number of subjects: 2
Study 24505303 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgiving judgments by player B
Number of subjects: 2
Study 23399618 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced atherosclerotic lesions (Group B)
Number of subjects: 564
Study 23399618 — intervention group
Group type: COMPARATOR
Intervention: No significant blood flow disorders (Group K)
Number of subjects: 564
Study 23399618 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 564
Study 23399618 — intervention group
Group type: EXPERIMENTAL
Intervention: Local thrombolysis
Number of subjects: 564
Study 23399618 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplastics and stenting after patency restoring
Number of subjects: 564
Study 23399618 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoro-femoral bypass implantation
Number of subjects: 564
Study 20395820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal ketorolac (0.5-2.0 mg)
Number of subjects: 57
Study 20395820 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal ketorolac (2.0 mg)
Number of subjects: 57
Study 20395820 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal saline (control)
Number of subjects: 57
Study 20395820 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine
Number of subjects: 57
Study 17567677 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective Public Health Intervention Studies Register
Number of subjects: 0
Study 15811567 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention focusing on personal understanding of illness
Number of subjects: 104
Study 15811567 — intervention group
Group type: COMPARATOR
Intervention: Care according to national guidelines for diabetes care
Number of subjects: 104
Study 10759273 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone followed by misoprostol 400 µg
Number of subjects: 1589
Study 10759273 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg mifepristone followed by misoprostol 400 µg
Number of subjects: 1589
Study 10759273 — intervention group
Group type: COMPARATOR
Intervention: 200 mg mifepristone
Number of subjects: 1589
Study 9031662 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing Assessment Decision Grid
Number of subjects: 282
Study 8518766 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased nurse support (n = 56)
Number of subjects: 103
Study 8518766 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 47)
Number of subjects: 103
Study 3103546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat emulsion administered at a constant rate over 24 hours, starting at 1 g/kg and increasing to a maximum of 4 g/kg
Number of subjects: 39
Study 3103546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat emulsion administered at a constant rate over 16 hours, starting at 1 g/kg and increasing to a maximum of 4 g/kg
Number of subjects: 39
Study 3103546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat emulsion administered at a constant rate of 4 g/kg a day over 24 hours
Number of subjects: 39
Study 31594857 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 14,007 IU/d
Number of subjects: 229
Study 31594857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 28346912 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 300 (300 IU/kg)
Number of subjects: 23
Study 28346912 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 1,000 (1,000 IU/kg)
Number of subjects: 23
Study 28346912 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 3,000 (3,000 IU/kg)
Number of subjects: 23
Study 28346912 — intervention group
Group type: COMPARATOR
Intervention: VENT (no treatment)
Number of subjects: 23
Study 26058417 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L/day of water for 30 days
Number of subjects: 34
Study 26058417 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied to be those consuming less water)
Number of subjects: 34
Study 23737079 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-laser treatment (9.6 µm, pulse-duration 20 µs, pulse-repetition-rate 20 Hz, average fluence 4.5 ± 0.5 J/cm², 20 laser pulses per spot)
Number of subjects: 20
Study 23737079 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish applications
Number of subjects: 20
Study 23737079 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-laser treatment
Number of subjects: 20
Study 21482568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil (600 mg iv every 12 h)
Number of subjects: 627
Study 21482568 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (1 g iv every 24 h)
Number of subjects: 627
Study 21482568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil and ceftriaxone
Number of subjects: 627
Study 19923069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (group M, n=23)
Number of subjects: 53
Study 19923069 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous respiration (group S, n=20)
Number of subjects: 53
Study 19923069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (group M)
Number of subjects: 53
Study 19923069 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous respiration (group S)
Number of subjects: 53
Study 17288832 — intervention group
Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 44
Study 17288832 — intervention group
Group type: COMPARATOR
Intervention: Open discectomy
Number of subjects: 44
Study 15154922 — intervention group
Group type: EXPERIMENTAL
Intervention: Two xylitol tablets two times a day (1.7 g xylitol d(‐1)) for 18 weeks
Number of subjects: 56
Study 15154922 — intervention group
Group type: EXPERIMENTAL
Intervention: Two xylitol tablets four times per day (3.4 g xylitol d(‐1)) for 18 weeks
Number of subjects: 56
Study 15154922 — intervention group
Group type: COMPARATOR
Intervention: No tablets (Control Group)
Number of subjects: 56
Study 11249900 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 5477
Study 11249900 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 5477
Study 9442992 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback
Number of subjects: 26
Study 9442992 — intervention group
Group type: COMPARATOR
Intervention: Additional therapy (Control)
Number of subjects: 26
Study 7686799 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (120 mg/day for 3 days)
Number of subjects: 15
Study 7686799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2437521 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin 1% creme rinse
Number of subjects: 1040
Study 2437521 — intervention group
Group type: COMPARATOR
Intervention: Lindane shampoo
Number of subjects: 1040
Study 30169600 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (3 g/day after a dose-escalation period over 4 weeks)
Number of subjects: 40
Study 30169600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30169600 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 40
Study 26835974 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent rLP2086 + HPV‐4
Number of subjects: 0
Study 26835974 — intervention group
Group type: COMPARATOR
Intervention: bivalent rLP2086 + saline
Number of subjects: 0
Study 26835974 — intervention group
Group type: COMPARATOR
Intervention: saline + HPV‐4
Number of subjects: 0
Study 26648210 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to the 'Babies' Portal' social network
Number of subjects: 22
Study 26648210 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to the social network)
Number of subjects: 22
Study 26648210 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (access to the social network)
Number of subjects: 22
Study 23332990 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent in-center hemodialysis (6-times-weekly)
Number of subjects: 332
Study 23332990 — intervention group
Group type: COMPARATOR
Intervention: Conventional in-center hemodialysis (3-times-weekly)
Number of subjects: 332
Study 23332990 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent nocturnal hemodialysis (6-times-weekly)
Number of subjects: 332
Study 23332990 — intervention group
Group type: COMPARATOR
Intervention: Conventional nocturnal hemodialysis (3-times-weekly)
Number of subjects: 332
Study 21551083 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) treatment
Number of subjects: 60
Study 21551083 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NAC treatment)
Number of subjects: 60
Study 18469257 — intervention group
Group type: EXPERIMENTAL
Intervention: Low zinc diets (<11 mg/d) for 4-8 weeks
Number of subjects: 109
Study 18469257 — intervention group
Group type: COMPARATOR
Intervention: High-phytate diets
Number of subjects: 109
Study 18469257 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-zinc, low-phytate diets for several weeks
Number of subjects: 109
Study 17288763 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 545
Study 17288763 — intervention group
Group type: COMPARATOR
Intervention: Early conservative strategy
Number of subjects: 545
Study 12965069 — intervention group
Group type: EXPERIMENTAL
Intervention: 10F pigtail catheter
Number of subjects: 30
Study 12965069 — intervention group
Group type: COMPARATOR
Intervention: 22F Councill‐tip catheter
Number of subjects: 30
Study 11128851 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive cycling at 65% VO2peak
Number of subjects: 10
Study 11128851 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive cycling at 75% VO2peak
Number of subjects: 10
Study 11128851 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive cycling at 85% VO2peak
Number of subjects: 10
Study 11128851 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive cycling at 95% VO2peak
Number of subjects: 10
Study 8136334 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Number of subjects: 1
Study 8136334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 2662981 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management of the third stage of labor
Number of subjects: 240
Study 2662981 — intervention group
Group type: COMPARATOR
Intervention: Physiologic management of the third stage of labor
Number of subjects: 240
Study 31142242 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of vitamin C, thiamine and hydrocortisone
Number of subjects: 0
Study 31142242 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone monotherapy
Number of subjects: 0
Study 28545508 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP)
Number of subjects: 280
Study 28545508 — intervention group
Group type: COMPARATOR
Intervention: Double-blind placebo (DBP)
Number of subjects: 280
Study 28545508 — intervention group
Group type: COMPARATOR
Intervention: Peppermint oil
Number of subjects: 280
Study 25311423 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (short-term, high-dose, perioperative use)
Number of subjects: 24
Study 25311423 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 24
Study 23521917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab treatment
Number of subjects: 162
Study 21849187 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute androgen suppression therapy
Number of subjects: 50
Study 21849187 — intervention group
Group type: COMPARATOR
Intervention: Chronic androgen suppression therapy
Number of subjects: 50